gene-editing

Modelling insertion efficiency for Prime Insertion Experiments

DeepGuide: a tool to predict CRIPR activity

Flexible pipeline for the detection of OFF-targets from GuideSeq related dataset

Candidate flanking-SNP marker panels for PGT-M linkage before an experiment. After one, parent of origin from SNP arrays, and a parental genotype reconstructed from haploid cells. Research use only.

A curated list of awesome resources for genetic engineering.

Annotate safe regions for gene editing and replace/recode codons.

An ML classifier built for Life Edit Therapeutics to detect edited vs unedited genes

Gene editor cutting/repair kinetics curve fitting script

A declarative DSL and compiler for reproducible gene-editing design — with LLM agents and an MCP server so any AI agent can drive it safely.

Real-Time Evolutionary AI Ecosystem for Intelligent Genomics and Bioengineering

基于多智能体协同的高通量基因编辑（ABE/CBE/PE/Cas/sgRNA）效率预测与任务调度中枢。 | A multi-agent task scheduling framework for high-throughput gene editing efficiency prediction, powered by LLM and Deep Learning.

JCAP CRISPR Mixscape Pipeline is a user-friendly R Shiny application for interactive single-cell CRISPR screen analysis. It enables rapid quality control, visualization, and differential expression discovery using Mixscape and Seurat, all in a point-and-click environment. Ideal for researchers working with Perturb-seq data.

Synthetic biology, dystopian film, and the natural limits — the rails — we were never meant to remove.

Elo Life Systems is a next-generation food and agriculture company based in Research Triangle Park, North Carolina, using molecular farming and gene-editing to turn high-yield crops into biofactories for natural food ingredients.

DGD-Cas9

Scribe Therapeutics is a clinical-stage biotechnology company founded in 2018 and headquartered in Alameda, California, engineering CRISPR-based genetic medicines through its proprietary "CRISPR by Design" platform.

Excision BioTherapeutics is a clinical-stage biotechnology company developing CRISPR-based gene-editing therapies intended to functionally cure serious viral infectious diseases. Its programs use multiplexed CRISPR/Cas approaches delivered via adeno-associated virus (AAV) to excise latent viral DNA from infected cells, with a lead candidate…

Shanghai Vitalgen BioPharma Co., Ltd. (Vitalgen), founded in March 2020 and headquartered in Shanghai, China, translates cutting-edge gene delivery and gene editing techniques into clinically effective treatments for patients with unmet medical needs.

Agenovir Corporation was a biotechnology company founded in 2014 to develop a novel class of human therapeutics targeting diseases caused by latent or persistent viral reservoirs. Built on CRISPR/Cas9 and other nuclease technology from the Stephen Quake lab at Stanford, it designed and simulated nucleases in silico at scale to disrupt…

AI-assisted platform for designing CRISPR experiments — from target selection to bench-ready protocols